Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to...
After achieving early breakthroughs in materials development, in vitro nanoparticle stimulation and signal reading, Subsense secures additional $10 mil...
Collaboration with Science Tokyo spinout underscores GlycoNex's integrated antibody development and manufacturing capabilities in support of first-in-cla...
Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, announced th...
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Co...
Financing led by Novartis Venture Fund and Forbion, with new investment from Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures ...
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-M...
New capacity at AstraZeneca’s Fredrick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines Four...
-Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited &ldquo...
Profluent, a leader in frontier AI for protein design, announced a $106 million financing co-led by Altimeter Capital and Bezos Expeditions, with p...
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, announced that it has raised...
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...
Third Rock Ventures and Parse Biosciences announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...
Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 20...
© 2025 Biopharma Boardroom. All Rights Reserved.
